Filing Flows › Metagenomi Therapeutics (MGX) › Q1 2026
Metagenomi Therapeutics (MGX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Metagenomi Therapeutics (MGX) reported revenue of $1.2M for the first quarter 2026 (Q1 2026), -70% from a year earlier and -68% from the quarter before.
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -68% | -70% |
| Operating profit | −$24.6M | — | — |
| Net earnings | −$23.1M | — | — |
| Operating cash flow | −$21.2M | — | — |
What changed
Revenue was $1.2M in Q1 2026, down 70% year over year and down 68% from the previous quarter.
Operating costs exceeded revenue by $24.6M, an operating margin of -1970.1%. Total costs fell 19% while revenue fell 70%. The quarter ended with a net loss of $23.1M, wider than the previous quarter's $22.5M loss.
Operating cash flow was −$21.2M. Non-cash charges added back $1.3M of depreciation and $2.6M of share-based compensation. Working capital and other items used $1.9M. Capital expenditures of $25K exceeded it, leaving free cash flow of −$21.2M.
Questions
What was Metagenomi Therapeutics' revenue in the first quarter 2026?
Metagenomi Therapeutics (MGX) reported revenue of $1.2M for the first quarter 2026 (Q1 2026), -70% from a year earlier and -68% from the quarter before.